Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : NEW Market Gems - Swing and Day Trades -- Ignore unavailable to you. Want to Upgrade?

To: Frederick Langford who wrote (411)	5/31/2001 9:39:25 PM
From: Jenna	Respond to of 1227

TEVA ...IPXL, ADRX Generic drug companies are looking mighty nice lately AZN can't keep IPXL and ADRX from have their generic drugs hit the market. Teva's generic Pepcid AC OK'd (TEVA) by Nicole Maestri Teva Pharmaceutical Industries said late Thursday that the FDA gave final approval for over-the-counter sales of its generic version of Pepcid AC. Teva (TEVA) said it expects to launch the Merck-developed drug immediately through a marketing alliance with Perrigo Co. (PRGO). The Jerusalem-based drug company said it will get 180 days to exclusively market the product, which treats heartburn, starting at the day of launch. Teva said annual sales of the brand in the United States are estimated to be $125 million. Shares closed up $2.81, or 5.1 percent, at $57.76 ahead of the announcement. In our view, Impax Laboratories (IPXL, $11.28, Buy) could also be a beneficiary, since the company has three pending Paragraph IV ANDAs covering Claritin-D 24 Hour, Claritin-D 12 Hour, and Claritin Reditabs. IPXL is likely first to file on Claritin-D 12 Hour...) 11.47 +0.19 (+1.7%): Another name to watch on the AstraZeneca (AZN) news is Impax, which also has filed to market a generic version of Prilosec. (ADRX) 67.97 +3.46 (+5.4%): Intraday spike in issue on reports that AstraZeneca's (AZN) Prilosec suit has been dismissed. AZN filed a suit earlier this month alleging that Andrx's generic form of heartburn and ulcer treatment infringed on AZN's patent.